Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 166

1.

Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization.

Polo V, Pasello G, Frega S, Favaretto A, Koussis H, Conte P, Bonanno L.

Oncotarget. 2016 Feb 25. doi: 10.18632/oncotarget.7732. [Epub ahead of print]

2.

MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data.

Pasello G, Urso L, Mencoboni M, Grosso F, Ceresoli GL, Lunardi F, Vuljan SE, Bertorelle R, Sacchetto V, Ciminale V, Rea F, Favaretto A, Conte P, Calabrese F.

Oncotarget. 2015 Dec 8;6(39):42053-66. doi: 10.18632/oncotarget.5974.

3.

Non-Small Cell Lung Cancer in a Very Young Woman: A Case Report and Critical Review of the Literature.

Polo V, Zago G, Frega S, Canova F, Bonanno L, Favaretto A, Bonaldi L, Bertorelle R, Conte P, Pasello G.

Am J Case Rep. 2015 Nov 3;16:782-9.

4.

Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment.

Urso L, Calabrese F, Favaretto A, Conte P, Pasello G.

Crit Rev Oncol Hematol. 2016 Jan;97:220-30. doi: 10.1016/j.critrevonc.2015.08.019. Epub 2015 Aug 22. Review.

PMID:
26358421
5.

Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

Scagliotti G, von Pawel J, Novello S, Ramlau R, Favaretto A, Barlesi F, Akerley W, Orlov S, Santoro A, Spigel D, Hirsh V, Shepherd FA, Sequist LV, Sandler A, Ross JS, Wang Q, von Roemeling R, Shuster D, Schwartz B.

J Clin Oncol. 2015 Aug 20;33(24):2667-74. doi: 10.1200/JCO.2014.60.7317. Epub 2015 Jul 13.

PMID:
26169611
6.

MRI-detectable cortical lesions in the cerebellum and their clinical relevance in multiple sclerosis.

Favaretto A, Lazzarotto A, Poggiali D, Rolma G, Causin F, Rinaldi F, Perini P, Gallo P.

Mult Scler. 2016 Apr;22(4):494-501. doi: 10.1177/1352458515594043. Epub 2015 Jul 10.

PMID:
26163070
7.

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.

Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD; LUX-Lung 8 Investigators.

Lancet Oncol. 2015 Aug;16(8):897-907. doi: 10.1016/S1470-2045(15)00006-6. Epub 2015 Jul 5.

PMID:
26156651
8.

The Parallel Analysis of Phase Sensitive Inversion Recovery (PSIR) and Double Inversion Recovery (DIR) Images Significantly Improves the Detection of Cortical Lesions in Multiple Sclerosis (MS) since Clinical Onset.

Favaretto A, Poggiali D, Lazzarotto A, Rolma G, Causin F, Gallo P.

PLoS One. 2015 May 26;10(5):e0127805. doi: 10.1371/journal.pone.0127805. eCollection 2015.

9.

Treatment of Unfit Patients With Advanced Non-Small-Cell Lung Cancer: Definition Criteria According an Expert Panel.

De Marinis F, Bria E, Baas P, Tiseo M, Camerini A, Favaretto AG, Gridelli C.

Clin Lung Cancer. 2015 Nov;16(6):399-405. doi: 10.1016/j.cllc.2015.04.008. Epub 2015 Apr 30. Review.

PMID:
25989953
10.

Epirubicin plus paclitaxel regimen as second-line treatment of patients with small-cell lung cancer.

Pasello G, Carli P, Canova F, Bonanno L, Polo V, Zago G, Urso L, Conte P, Favaretto A.

Anticancer Res. 2015 Apr;35(4):2183-9.

PMID:
25862876
11.

Disease-modifying drugs reduce cortical lesion accumulation and atrophy progression in relapsing-remitting multiple sclerosis: results from a 48-month extension study.

Rinaldi F, Perini P, Atzori M, Favaretto A, Seppi D, Gallo P.

Mult Scler Int. 2015;2015:369348. doi: 10.1155/2015/369348. Epub 2015 Feb 23.

12.

Results of surgical resection after induction chemoradiation for Pancoast tumours †.

Marulli G, Battistella L, Perissinotto E, Breda C, Favaretto AG, Pasello G, Zuin A, Loreggian L, Schiavon M, Rea F.

Interact Cardiovasc Thorac Surg. 2015 Jun;20(6):805-11; discussion 811-2. doi: 10.1093/icvts/ivv032. Epub 2015 Mar 10.

13.

Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials.

Di Maio M, Gallo C, Leighl NB, Piccirillo MC, Daniele G, Nuzzo F, Gridelli C, Gebbia V, Ciardiello F, De Placido S, Ceribelli A, Favaretto AG, de Matteis A, Feld R, Butts C, Bryce J, Signoriello S, Morabito A, Rocco G, Perrone F.

J Clin Oncol. 2015 Mar 10;33(8):910-5. doi: 10.1200/JCO.2014.57.9334. Epub 2015 Jan 26.

14.

Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer.

Cappuzzo F, Finocchiaro G, Grossi F, Bidoli P, Favaretto A, Marchetti A, Valente ML, Cseh A, Clementi L, Massey D, Santoro A.

J Thorac Oncol. 2015 Apr;10(4):665-72. doi: 10.1097/JTO.0000000000000442.

15.

Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.

Ellis PM, Shepherd FA, Millward M, Perrone F, Seymour L, Liu G, Sun S, Cho BC, Morabito A, Leighl NB, Stockler MR, Lee CW, Wierzbicki R, Cohen V, Blais N, Sangha RS, Favaretto AG, Kang JH, Tsao MS, Wilson CF, Goldberg Z, Ding K, Goss GD, Bradbury PA; NCIC CTG; Australasian Lung Cancer Trials Group; NCI Naples Clinical Trials Unit.

Lancet Oncol. 2014 Nov;15(12):1379-88. doi: 10.1016/S1470-2045(14)70472-3. Epub 2014 Oct 15.

PMID:
25439692
16.

Classification of first-episode psychosis: a multi-modal multi-feature approach integrating structural and diffusion imaging.

Peruzzo D, Castellani U, Perlini C, Bellani M, Marinelli V, Rambaldelli G, Lasalvia A, Tosato S, De Santi K, Murino V, Ruggeri M, Brambilla P; PICOS-Veneto Group.

J Neural Transm (Vienna). 2015 Jun;122(6):897-905. doi: 10.1007/s00702-014-1324-x. Epub 2014 Oct 26.

PMID:
25344845
17.

A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors.

Petrini I, Meltzer PS, Kim IK, Lucchi M, Park KS, Fontanini G, Gao J, Zucali PA, Calabrese F, Favaretto A, Rea F, Rodriguez-Canales J, Walker RL, Pineda M, Zhu YJ, Lau C, Killian KJ, Bilke S, Voeller D, Dakshanamurthy S, Wang Y, Giaccone G.

Nat Genet. 2014 Aug;46(8):844-9. doi: 10.1038/ng.3016. Epub 2014 Jun 29.

PMID:
24974848
18.

Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: final results of an International randomized phase II study (NAVotrial 01).

Bennouna J, Havel L, Krzakowski M, Kollmeier J, Gervais R, Dansin E, Serke M, Favaretto A, Szczesna A, Cobo M, Ciuffreda L, Jassem J, Nicolini M, Ramlau R, Amoroso D, Melotti B, Almodovar T, Riggi M, Caux NR, Vaissière N, Tan EH.

Clin Lung Cancer. 2014 Jul;15(4):258-65. doi: 10.1016/j.cllc.2014.04.007. Epub 2014 May 15.

PMID:
24954228
19.

Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study.

de Marinis F, Ardizzoni A, Fontanini G, Grossi F, Cappuzzo F, Novello S, Santo A, Lorusso V, Cortinovis D, Iurlaro M, Galetta D, Gridelli C; LIFE Study Team.

Clin Lung Cancer. 2014 Sep;15(5):338-45.e1. doi: 10.1016/j.cllc.2014.04.004. Epub 2014 May 14.

PMID:
24925809
20.

Synergistic antitumor activity of recombinant human Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in combination with carboplatin and pemetrexed in malignant pleural mesothelioma.

Pasello G, Urso L, Silic-Benussi M, Schiavon M, Cavallari I, Marulli G, Nannini N, Rea F, Ciminale V, Favaretto A.

J Thorac Oncol. 2014 Jul;9(7):1008-17. doi: 10.1097/JTO.0000000000000198.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk